The flawed assumption
Established measures of bone health are often assumed to be fit for purpose in Rare Bone Diseases.
Rare Bone Disease Imaging Biomarker Initiative (RBD-IBI)
Most still lack a fit-for-purpose quantitative imaging biomarker.
A fragility fracture is a clear sign that something is wrong. But when bone density and structural scans can look completely normal, doctors, patients and families are left asking the same critical question:
This initiative exists to help solve that exact conundrum.
To advance quantitative imaging biomarkers that objectively measure skeletal pathology in Rare Bone Diseases.
Research. Hope. Earlier Answers.
What happens when objective measurement is missing.
Therapies are advancing. Measurement must advance with them.
The consequences affect patients and families, clinicians, researchers, pharmaceutical and biotechnology developers, investors and funders, regulators, governments and healthcare systems.
A promising therapy may be evaluated using an endpoint that is familiar, available and well validated in another skeletal disease, yet insufficiently sensitive or biologically matched to the Rare Bone Disease pathology the therapy is intended to change.
Investing early in the right biomarker can protect a much larger investment in drug development and clinical trials.
Established measures of bone health are often assumed to be fit for purpose in Rare Bone Diseases.
RBDs arise from diverse biological causes and can produce skeletal pathologies fundamentally different from osteoporosis.
A tool developed to measure osteoporosis may not measure the pathology driving a Rare Bone Disease.
Most established quantitative bone measurements were developed primarily around osteoporosis — particularly bone loss and related structural deterioration. Because these tools are widely accepted as measures of “bone health”, they can be carried into Rare Bone Disease research with the implicit assumption that they measure skeletal health more generally.
But different bone diseases can fail for different biological reasons. A measurement can be technically excellent for the biological target it was designed to assess, yet still be biologically mismatched to the pathology of the RBD being studied.
A technically excellent measurement can still be biologically wrong for the disease being studied.
That assumption can hide the measurement gap itself.
If an appropriate skeletal biomarker is assumed to already exist, there is less reason to first define the disease-relevant pathology or invest in developing the measurement actually needed. Existing tools may therefore continue to be selected, adapted and validated in RBDs without first establishing that they adequately measure the biological abnormality driving the disease.
Do not ask first
“Which bone test do we already have?”
Ask first
“What skeletal pathology does this disease produce — and how should it be measured?”
This is the conceptual shift at the heart of RBD-IBI.
A familiar measurement is not necessarily a fit-for-purpose measurement.
Measuring the wrong biological target more precisely does not solve the RBD measurement gap.
“You cannot understand what you cannot objectively measure. Dedicated imaging biomarkers are the foundation of understanding, innovation, and better care for Rare Bone Diseases.”
Rare Bone Diseases Deserve the Same Imaging Biomarker Innovation that Transformed Osteoporosis.
Two principles give a clear introduction to the RBD-IBI scientific thinking — without reproducing the complete Consensus Framework.
Principle 1
Osteoporosis-derived measurements were developed primarily around bone loss and related structural deterioration. Many RBDs arise from fundamentally different skeletal pathologies and therefore may not be adequately represented or detected by osteoporosis-derived measurements.
“Do not inherit a measurement paradigm from another disease. RBDs are not osteoporosis, and forcing rare skeletal pathology into an osteoporosis-derived measurement framework is a fundamental measurement error.”
This does not make established technologies poor technologies. They may measure the skeletal properties they were designed to assess extremely well. What should not be assumed is that those same properties necessarily represent the disease-defining pathology of every Rare Bone Disease.
Principle 2
The biological cause of an RBD and the pathophysiological mechanism by which it produces skeletal abnormality determine the biological target that an imaging biomarker must measure. The biological target should not be reverse-engineered from the capabilities, availability, convenience or familiarity of an existing technology.
“Biology and pathophysiology define what must be measured; technology determines how it is measured — not what should be measured.”
We don’t treat a label. We don’t treat a property. We treat the pathology — so we should measure the pathology.
Once the need for a fit-for-purpose biomarker is recognised, Rare Bone Diseases present a second challenge: the patients, expertise, imaging and evidence required to develop and validate that biomarker are often dispersed and fragmented.
RBD-IBI is designed not only to identify the need for better biomarkers, but also to address the practical limitations that have made those biomarkers difficult to develop and validate in Rare Bone Diseases.
Where different Rare Bone Diseases are demonstrated to share the same biologically defined skeletal pathology, RBD-IBI seeks to determine whether those diseases can form a scientifically justified group for shared biomarker development and validation.
This can allow patients, imaging, datasets, evidence, expertise, controls, infrastructure and validation resources to be brought together where scientifically appropriate, rather than repeatedly rebuilding the same development pathway disease by disease.
Rare diseases may be individually small. Shared pathology can create a larger scientific opportunity.
The measurement blind spot creates the need. Rarity makes solving it difficult. RBD-IBI is designed to address both.
RBD-IBI proposes a biology-first approach in which the skeletal pathology produced by the disease is defined before selecting the technology used to measure it.
Where etiologically distinct Rare Bone Diseases are demonstrated to share the same clinically relevant skeletal pathology, RBD-IBI asks whether that Shared Skeletal Pathology can support shared measurement, evidence generation and validation across those diseases.
This is important because the RBD-IBI approach addresses both major problems:
Identify what actually needs to be measured.
Use shared biology, where scientifically justified, to overcome some of the limitations imposed by rarity.
Every visitor should be able to follow the logic — whether or not they already know RBD-IBI terminology. The scientific terms are shown underneath each step.
Start with the rare bone disease
Rare Bone Disease
What is happening in the skeleton?
Identify the skeletal abnormality
What is wrong in the skeleton?
Defined Skeletal Pathology
Ask whether other rare bone diseases share it
Is the same pathology shared by other RBDs?
Shared Skeletal Pathology (SSP)
Define which diseases can be studied together
Which diseases can be studied together?
RBD–SSP Group Population
Bring together the imaging, data & evidence
What imaging and evidence already exist?
Develop a way to measure the pathology
How can the pathology be measured?
Shared Imaging Biomarker
Test that the measurement works
Does the measurement work reliably?
Fit-for-Purpose Validation for a Defined Context of Use
Put the measurement to use
Can it improve research, trials and care?
Research Clinical Trials Therapeutic Development Regulatory Science Clinical Care
Shared pathology enables shared measurement.
Shared measurement enables shared evidence generation.
RBD-BRIDGE™ is the interactive digital platform being developed to operationalise this framework. Find out more
Elements of the RBD-IBI framework, delivered as focused projects — each currently in development.
Project 001
In Development Consensus Review — Open
Develop and publish an international scientific framework to address the imaging-biomarker gap in Rare Bone Diseases by establishing standards for identifying disease-relevant skeletal pathology and for the discovery, development, validation and fit-for-purpose use of quantitative imaging biomarkers.
This is the foundational RBD-IBI scientific project addressing the measurement gap described throughout the homepage.
Explore the frameworkRare Bone Disease Biomarker Research, Imaging, Data & Global Evidence Platform
Project 002
In Development
An interactive, expert-governed digital platform connecting patients, clinicians, researchers and industry. It integrates RBD knowledge, imaging repositories, shared biomarker development, clinical trials and emerging therapies.
Learn about RBD-BRIDGE™Project 003
Coming Soon
Future RBD-IBI initiative.
Project 004
Coming Soon
Future RBD-IBI initiative.
RBD-BRIDGE™ is Project 002 within RBD-IBI - not a separate organisation. It is the interactive, expert-governed operational platform that sits behind the RBD-IBI framework to support structured participation, evidence contribution and implementation workflows.
The RBD-IBI website provides information, education and public engagement. RBD-BRIDGE™ enables patients and families, clinicians, researchers and partners to contribute imaging, relevant clinical information or lived experience under appropriate consent and governance; register interest in research and validation studies; contribute priorities and questions; participate in structured consultations or surveys; and connect appropriately with RBD-IBI research and biomarker programmes.
Platform under development.
Enter RBD-BRIDGE™RBD-IBI is an independent, international, clinician-led and platform-independent scientific initiative uniting patients, clinicians, researchers, academia, industry, regulators, governments, NGOs and funders to advance fit-for-purpose quantitative imaging biomarkers for Rare Bone Diseases.
Our Charter, mission, vision and broader scientific principles — and what Research. Hope. Earlier Answers. means in practice — are set out in full on our About page.
Read about our Charter, mission and principlesIf you or someone you love is affected by a rare bone disease, you may have questions and no easy answers yet. Our promise is simple: clear, trustworthy information in plain language, and routes to the help that exists.
Planned with patient partners in mind — this is what we aim to offer here:
RBD-IBI is relevant to, and welcomes participation from, the full international Rare Bone Disease ecosystem.
Reviews, guidelines and publications — curated here as the evidence grows.
Browse publicationsGoverned imaging and datasets — consent-based, ethically reviewed and accessible under clear conditions — ready for rigorous secondary research.
Access the resourcesProtocols and processes designed to help sites run studies to the shared standard.
See the guidesA durable funding and governance model is designed to keep the initiative useful long after individual programmes end — protecting data, relationships and trust.
Read moreInterest in RBD-IBI has already been expressed by researchers and clinicians in several countries. Verified figures will be published here as partnerships, studies and resources are confirmed — openly, and never invented.
RBD-IBI is bringing together researchers, clinicians, imaging scientists, patients, academic institutions and industry partners interested in advancing quantitative imaging biomarkers for rare bone diseases.
Whether you lead research, deliver care or live with RBD - there is a way in. The website provides information and education; use RBD-BRIDGE™ for structured participation and collaboration.